Palvella Therapeutics
PVLAPalvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations that lack FDA-approved treatments.
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations that lack FDA-approved treatments. The company leverages its proprietary, patented QTORIN platform to generate topical product candidates designed to penetrate deep skin layers and treat localized disease manifestations with minimal systemic absorption. Its primary objective is to advance its lead candidates to establish first-line therapies and new standards of care for rare dermatological conditions.
The company is a clinical-stage pioneer utilizing a proprietary deep-skin delivery platform to develop first-in-disease treatments for rare conditions with no current FDA-approved therapies.
Questions, answered.
- What is Palvella Therapeutics's market cap?
- Palvella Therapeutics (PVLA) has a market capitalization of $2.0B and trades on XNAS.
- Who are Palvella Therapeutics's competitors?
- Palvella Therapeutics's key competitors include Protara Therapeutics, Inc., Relay Therapeutics, Inc., Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Palvella Therapeutics partner with?
- Palvella Therapeutics's notable partners include Ligand Pharmaceuticals, Inc., Yale University, Nemera Le Tréport SAS.
- What subsidiaries does Palvella Therapeutics have?
- Palvella Therapeutics's subsidiaries include Legacy Palvella.
- Where is Palvella Therapeutics headquartered?
- Palvella Therapeutics is headquartered in United States of America. It has been publicly traded since 2024.